KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Depreciation and Depletion (2022 - 2025)

Historic Depreciation and Depletion for Twist Bioscience (TWST) over the last 4 years, with Q4 2025 value amounting to $5.9 million.

  • Twist Bioscience's Depreciation and Depletion fell 327.87% to $5.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $23.8 million, marking a year-over-year decrease of 1018.87%. This contributed to the annual value of $23.8 million for FY2025, which is 1282.05% down from last year.
  • Latest data reveals that Twist Bioscience reported Depreciation and Depletion of $5.9 million as of Q4 2025, which was down 327.87% from $5.7 million recorded in Q3 2025.
  • Twist Bioscience's Depreciation and Depletion's 5-year high stood at $7.3 million during Q3 2023, with a 5-year trough of $3.9 million in Q4 2022.
  • Over the past 4 years, Twist Bioscience's median Depreciation and Depletion value was $6.4 million (recorded in 2024), while the average stood at $6.2 million.
  • In the last 5 years, Twist Bioscience's Depreciation and Depletion skyrocketed by 7692.31% in 2023 and then crashed by 1714.29% in 2025.
  • Over the past 4 years, Twist Bioscience's Depreciation and Depletion (Quarter) stood at $3.9 million in 2022, then skyrocketed by 76.92% to $6.9 million in 2023, then decreased by 11.59% to $6.1 million in 2024, then dropped by 3.28% to $5.9 million in 2025.
  • Its Depreciation and Depletion stands at $5.9 million for Q4 2025, versus $5.7 million for Q3 2025 and $5.8 million for Q2 2025.